- Home
- DCGO vs RVNC Comparison
DCGO vs RVNC Comparison
Compare DCGO & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- RVNC
- Stock Information
- Founded
- DCGO 2015
- RVNC 1999
- Country
- DCGO United States
- RVNC United States
- Employees
- DCGO N/A
- RVNC N/A
- Industry
- DCGO Managed Health Care
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- DCGO Health Care
- RVNC Health Care
- Exchange
- DCGO Nasdaq
- RVNC Nasdaq
- Market Cap
- DCGO 327.4M
- RVNC 546.4M
- IPO Year
- DCGO N/A
- RVNC 2014
- Fundamental
- Price
- DCGO $3.42
- RVNC $5.28
- Analyst Decision
- DCGO Strong Buy
- RVNC Buy
- Analyst Count
- DCGO 5
- RVNC 10
- Target Price
- DCGO $6.10
- RVNC $10.86
- AVG Volume (30 Days)
- DCGO 431.0K
- RVNC 1.8M
- Earning Date
- DCGO 11-07-2024
- RVNC 11-06-2024
- Dividend Yield
- DCGO N/A
- RVNC N/A
- EPS Growth
- DCGO 393.09
- RVNC N/A
- EPS
- DCGO 0.28
- RVNC N/A
- Revenue
- DCGO $742,836,424.00
- RVNC $251,178,000.00
- Revenue This Year
- DCGO $1.17
- RVNC $20.36
- Revenue Next Year
- DCGO N/A
- RVNC $31.66
- P/E Ratio
- DCGO $12.35
- RVNC N/A
- Revenue Growth
- DCGO 64.49
- RVNC 40.23
- 52 Week Low
- DCGO $2.75
- RVNC $2.30
- 52 Week High
- DCGO $6.90
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- DCGO 53.79
- RVNC 43.99
- Support Level
- DCGO $3.20
- RVNC $5.10
- Resistance Level
- DCGO $3.47
- RVNC $5.43
- Average True Range (ATR)
- DCGO 0.15
- RVNC 0.17
- MACD
- DCGO 0.03
- RVNC 0.02
- Stochastic Oscillator
- DCGO 87.80
- RVNC 64.29
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.